Email: c.newman@sheffield.ac.uk

Research profile and key clinical specialties

My primary research interest is in non-viral gene therapy, especially the use of ultrasound as a delivery technology. Interests in pulmonary hypertension and vascular biology.

My roles and responsibilities include Faculty Director of Research & Innovation for the Faculty of Medicine, Dentistry & Health Director, NIHR Sheffield Clinical Research Facility Professor of Clinical Cardiology and Honorary Consultant Cardiologist.

Two key publications

• Hameed AG, Arnold ND, Chamberlain J, Pickworth J, Paiva C, Dawson S, Cross S, Long L, Zhao L, Morrell NW, Crossman DC, Newman CM, Kiely DG, Francis SE, Lawrie A Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med (2012) 209 (11): 1919-1935
• Akowuah EF, Gray C, Sheridan PJ, Lawrie A, Su CH, Bettinger T, Brisken AF, Gunn J, Crossman DC, Francis SE, Baker AH, Newman CM. Ultrasound-mediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. Gene Therapy (2005) 12(14):1154-7

Possible PhD projects

• Ultrasound enhanced gene therapy of BMP9 to prevent and reverse experimental pulmonary arterial hypertension in rodent models.

More information

Have served on NIHR Doctoral Fellowship Panel and BHF Project Grant Panel. Previous Chair of British Society for Cardiovascular Research and Secretary and Treasurer of British Atherosclerosis Society.

Keywords: Pulmonary, hypertension, vascular, dentistry, Cardiologist, cardiology, TIMP-3, Christopher, Newman, Sheffield

Related